Edition:
United States

Pluristem Therapeutics Inc (PSTI.O)

PSTI.O on Consolidated Issue listed on NASDAQ Capital Market

1.84USD
23 Oct 2017
Change (% chg)

$0.08 (+4.25%)
Prev Close
$1.76
Open
$1.86
Day's High
$1.87
Day's Low
$1.78
Volume
632,789
Avg. Vol
411,563
52-wk High
$2.02
52-wk Low
$1.04

Latest Key Developments (Source: Significant Developments)

FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy
Thursday, 19 Oct 2017 07:30am EDT 

Oct 19 (Reuters) - Pluristem Therapeutics Inc :FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy as treatment for acute radiation syndrome.  Full Article

Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Pluristem Therapeutics Inc ::Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture.Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture.Pluristem- ‍ proposed Phase III trial will be double-blind, randomized, placebo-controlled trial with about 180 patients enrolled in U.S. and Europe​.Pluristem Therapeutics Inc - Pluristem plans to use results of trial of PLX-PAD to achieve marketing approval in both U.S. And Europe.Pluristem Therapeutics Inc - ‍plans to submit investigational new drug (IND) and clinical trial application (CTA) for trial in coming months​.  Full Article

U.S. FDA grants fast track designation to Pluristem's PLX-PAD for treating Critical Limb Ischemia
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Pluristem Therapeutics Inc :U.S. FDA grants fast track designation to Pluristem's PLX-PAD for the treatment of Critical Limb Ischemia (cli).Pluristem Therapeutics Inc - Pluristem's ongoing phase III cli trial has been selected for accelerated approval pathways in both U.S. and Europe.  Full Article

U.S. DOD to conduct studies of Pluristem’s PLX-R18 in a new ARS project
Wednesday, 16 Aug 2017 07:30am EDT 

Aug 16 (Reuters) - Pluristem Therapeutics Inc :U.S. Department of Defense to conduct studies of Pluristem’s PLX-R18 in a new ars project for use before radiation exposure.Pluristem Therapeutics Inc - DOD studies seek to test effectiveness of PLX-R18 as a novel medical countermeasure for acute radiation syndrome.Pluristem Therapeutics Inc - DOD studies will be conducted in parallel with ongoing ARS project with nih.  Full Article

Pluristem advances its limb ischemia study, targeting initiation at 40 active sites by the year end
Monday, 10 Jul 2017 07:00am EDT 

July 10 (Reuters) - Pluristem Therapeutics Inc :Pluristem advances its multinational phase III critical limb ischemia study, targeting initiation at 40 active sites by the end of 2017.‍Austria's regulatory health agency clears CLI study and joins U.S., U.K., and Germany in conducting 250-patient phase III trial​.‍Phase III CLI trial has received an $8 million grant from European Union's horizon 2020 program​.  Full Article

Pluristem Therapeutics says on July 7, co entered into an at market issuance sales agreement - SEC Filing
Friday, 7 Jul 2017 08:40am EDT 

July 7 (Reuters) - Pluristem Therapeutics Inc :Pluristem Therapeutics Inc - On July 7, 2017, co entered into an at market issuance sales agreement - SEC Filing.Pluristem Therapeutics Inc - Pluristem may issue and sell shares of common stock having aggregate offering price of up to $80 million from time to time.  Full Article

Pluristem Therapeutics files for mixed shelf of up to $200 mln - SEC Filing
Friday, 23 Jun 2017 09:24am EDT 

June 23 (Reuters) - Pluristem Therapeutics Inc :Pluristem Therapeutics Inc files for mixed shelf of up to $200 million - SEC Filing.  Full Article

Pluristem Therapeutics says Yaky Yanay appointed co-CEO
Friday, 23 Jun 2017 08:14am EDT 

June 23 (Reuters) - Pluristem Therapeutics Inc :Says Yaky Yanay appointed co-CEO.  Full Article

Pluristem provides results from acute radiation syndrome preclinical study
Wednesday, 3 May 2017 07:00am EDT 

May 3 (Reuters) - Pluristem Therapeutics Inc :Pluristem therapeutics inc- announces promising results from non-human primate pilot study of plx-r18 in acute radiation syndrome.Pluristem-Plx-R18 cells did not increase leukocyte levels in non-irradiated nhps; all plx-treated groups showed improvements in survival rates versus untreated groups.Pluristem therapeutics inc- data will inform a pivotal trial that could support marketing authorization under fda's animal rule regulatory pathway.  Full Article

Pluristem appoints Erez Egozi as CFO
Wednesday, 29 Mar 2017 04:00pm EDT 

Pluristem Therapeutics Inc : Pluristem launches co-CEO structure and appoints new CFO . Pluristem Therapeutics Inc - Erez Egozi appointed as chief financial officer . Pluristem Therapeutics Inc - Yaky Yanay appointed co-chief executive officer to serve together with co-chief executive officer Zami Aberman .Pluristem Therapeutics Inc - Erez Egozi appointed as chief financial officer.  Full Article

BRIEF-Pluristem expands its reach in the treatment of impaired hematopoietic systems

* Pluristem expands its reach in the treatment of impaired hematopoietic systems with a European patent covering PLX-R18 in chemotherapy, ARS, genetic disorders and autoimmune diseases Source text for Eikon: Further company coverage: